EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Recent cannabis exposure and acute nicotine effects: insights from randomized, double-blind, placebo-controlled intravenous nicotine studies

Gabriel P A Costa iD, R Ross MacLean, Mehmet Sofuoglu, Joao P De Aquino iD

International Journal of Neuropsychopharmacology · 2026

DOI: 10.1093/ijnp/pyag030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2026. Verfasst von Gabriel P A Costa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States. Hauptthemen laut MEDLINE: Nicotine, Nicotinic Agonists, Marijuana Smoking. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VA New England (VISN 1) Mental Illness Research, Education and Clinical Center (MIRECC), NIDA NIH HHS, NIDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cannabis–nicotine co-use is common and may affect cessation outcomes, yet whether recent cannabis exposure alters nicotine’s acute effects in humans remains unclear. We examined whether recent, non-daily cannabis exposure modulates the acute subjective effects of intravenous (IV) nicotine.

Methods

We pooled data from 2 randomized, double-blind, placebo-controlled studies using IV nicotine to isolate nicotine’s pharmacodynamics in adults who smoke tobacco cigarettes (N = 60). Participants completed 3 sessions (placebo, 0.1 mg, 0.2 mg nicotine/70 kg). Recent cannabis exposure was defined a priori (past-30-day use with positive urine 11-nor-9-carboxy-delta-9-tetrahydrocannabinol vs no past-30-day use with negative screen). Primary outcomes were peak Drug Effects Questionnaire (DEQ) composites—stimulatory, pleasurable, aversive—within 10 minutes post-infusion. Secondary outcomes included nicotine self-administration behavior (proportion of nicotine choices) and cardiovascular responses (heart rate, blood pressure). Linear mixed-effects models included dose, cannabis exposure, sex, and FTND.

Results

Nicotine increased all DEQ domains dose-dependently (P < .0001). Aversive effects showed a significant dose x cannabis exposure interaction (χ2 = 13.31, P = .001): participants with recent cannabis exposure reported greater aversive responses at 0.2 mg (Cohen’s d’ = 0.83), with minimal between-group differences at placebo/0.1 mg. Nicotine self-administration did not differ by cannabis exposure status, and no dose x cannabis exposure interactions were observed for cardiovascular responses.

Conclusions

Recent, non-daily cannabis exposure is thus associated with selectively greater aversive responses to a clinically relevant IV nicotine dose, without differential cardiovascular reactivity or altered nicotine choice. These findings support a shift in the aversive limb of nicotine’s dose–response and inform mechanistic and clinical studies on how cannabis exposure shapes nicotine reinforcement and cessation outcomes. Clinical trial registration NCT01495819, https://clinicaltrials.gov/study/NCT01495819.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NicotineNicotinic AgonistsMarijuana SmokingHumansDouble-Blind MethodMaleAdultFemaleHeart RateYoung AdultBlood PressureSelf AdministrationDose-Response Relationship, DrugAdministration, IntravenousInfusions, Intravenous

Stichwörter der Autor:innen

aversioncannabisdrug reinforcementnicotinereward

Substanzen

NicotineNicotinic Agonists

Autor:innen und Institutionen

  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
  • Clinical Neuroscience Research Unit (CNRU), Connecticut Mental Health Center (CMHC), New Haven, CT, United States.
  • VA Connecticut Healthcare System, West Haven, CT, USA.

ORCID-Profile: Gabriel P A Costa, Joao P De Aquino

Förderung

  • VA New England (VISN 1) Mental Illness Research, Education and Clinical Center (MIRECC)
  • NIDA NIH HHS
  • NIDA
  • FDA Center for Tobacco Products (CTP)
  • National Institute on Drug Abuse

Zitieren

APA

Costa, G. P. A., MacLean, R. R., Sofuoglu, M., & De Aquino, J. P. (2026). Recent cannabis exposure and acute nicotine effects: insights from randomized, double-blind, placebo-controlled intravenous nicotine studies. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyag030

Vancouver

Costa GPA, MacLean RR, Sofuoglu M, De Aquino JP. Recent cannabis exposure and acute nicotine effects: insights from randomized, double-blind, placebo-controlled intravenous nicotine studies. International Journal of Neuropsychopharmacology. 2026. doi:10.1093/ijnp/pyag030

BibTeX
@article{Costa2026,
  author = {Costa, Gabriel P A and MacLean, R Ross and Sofuoglu, Mehmet and De Aquino, Joao P},
  title = {Recent cannabis exposure and acute nicotine effects: insights from randomized, double-blind, placebo-controlled intravenous nicotine studies},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  doi = {10.1093/ijnp/pyag030}
}
Kostenlos starten →